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BACKGROUND Transcatheter Aortic Valve Replacement (TAVR) is
frequently used to treat patients with symptomatic, severe aortic
stenosis in whom surgery is considered to be high-risk or contra-
indicated. Post-procedural para-valvular leak (PVL) remains a signif-
icant issue with a complex etiology. Our objective was to investigate
anatomic and procedural predictors of post-TAVR PVL in patients
undergoing implantation of the self-expandable Corevalve trans-
catheter heart valve (THV).
METHODS 82 patients undergoing TAVR with Corevalve THV who
underwent pre-procedural multi-detector row computed tomography
(MDCT) and intra-procedural transesophageal echocardiography
(TEE) were included. PVL severity was graded using modiﬁed VARC-2
criteria. Annulus dimensions, annulus angulation from the axial
plane, and calcium volume scores1 were measured by MDCT. Pre-
implant peak transaortic velocity, aortic valve effective oriﬁce area
(EOA), left-ventricular stroke volume (LV SV), left-ventricular ejection
fraction (LVEF), and post-implant THV dimensions, implant depth,
and PVL were assessed by TEE. An independent t-test was used to
compare groups.
RESULTS Mean age was 83.0 years and 54% of patients were female.
39 patients (49%) underwent balloon post-dilatation. Age and gender
did not signiﬁcantly differ between patients with > mild and  mild
PVL. Out of the 82 patients studied, 57 had < mild, 14 had mild,
4 had mild-moderate, and 7 had moderate PVL at the end of the
case. No patient had > moderate PVL. Calcium volume score,
annulus angle, baseline transaortic peak velocity, and device size
were signiﬁcantly higher in the > mild PVL group (Table 1). MDCT-
derived % perimeter oversizing, LVEF, and a novel variable of THV
inﬂow expansion (3-dimensional TEE-derived THV inﬂow area/
native annulus area) were signiﬁcantly lower in the > mild PVL
group. Native annulus eccentricity, LV SV, baseline aortic valve EOA,
and echo-derived implant depth were not signiﬁcantly different
between the 2 groups.
Table 1. Variables dichotomized by PVL severityPVL £ mild (n[71) PVL > mild (n[11) p-valuePre-implant variablesAnnulus angle* () 44  11 50  9 0.005
Calcium Volume (mm3) 921  608 1588  563 0.001
Annulus eccentricity 1.3  0.1 1.3  0.1 0.94
Peak transaortic
velocity (m/s)3.6 4.1 0.006EOA (cm2) 0.65  0.18 0.63  0.18 0.75
LV Stroke Volume (ml) 57  18 59  16 0.64
LVEF (%) 54 16 40  21 0.01
Post-implant
variables% Oversizing 18  0.004 13  0.004 0.02
Inﬂow expansion 0.95  0.03 0.69  0.05 0.007
Implant depth, mm 5.50 3.9 6.5  14.8 0.42
THV size, mm 27.5  2.4 29.5  1.5 0.01CONCLUSIONS Among patients undergoing TAVR with a self-
expanding Corevalve THV, PVL severity was related to higher annulus
angle, calcium volume, baseline peak transaortic velocity, THV size,-
lower LVEF, %oversizing, and a novel variable of inﬂow expansion.
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BACKGROUND Transfemoral/Trancutaneous aortic valve implanta-
tion (TAVI) is an alternative to surgical aortic valve replacement
(SAVR) in high risk patients with severe symptomatic aortic stenosis
with good hemodynamic and clinical results. But higher rates of sig-
niﬁcant conduction disturbances with the need for post-interven-
tional pacemaker implantation (PMI) have been reported. Therefore,
the aim of analysis was to determine the frequency of conduction
disturbances and the need for PMI after TAVI and the impact on
procedural and mid-term outcome.
METHODS Patient receiving TAVI at our center between 2006 and
2014 have been enrolled in a prospective single center registry. The
occurrence of conduction abnormalities and the need for PMI has
been recorded in 1700 consecutive patients treated predominately
with the transfemoral approach under local anesthesia. The database
was analyzed with regards to signiﬁcant conduction disturbances, the
need for PMI and the impact on survival.
RESULTS Patients with a mean age of 806 years, a mean STS Score
of 8.56.2% and a logEuroSCORE of 19.813.6% were treated pre-
dominately with the self-expandable Medtronic Core Valve System
(MCV, 64%). The balloon-expandable Edwards SAPIEN valves, other
devices and valve-in-valve procedures have been performed less
frequently (29%, 7%, 4%). The overall pacemaker rate was 28.1% at 30-
days and signiﬁcantly higher in patients treated with the MCV (33.1%)
and other valve types (24.3%) as compared with patients treated with
the Edwards SAPIEN (17.9%; p<0.036). The predominant conduction
disturbances were high grade AV-Block or signiﬁcant bradycardia in
84% of cases. The length of hospital stay and mortality after 30-days
did not differ signiﬁcantly (147 vs. 138 days, p>0.05; 7.0% vs. 7.3%,
p>0.05), whereas patients with a pre-existing PM could be discharged
earlier (103days, p<0.05). The one-year mortality of patients with
PMI after TAVI was not signiﬁcantly different either (20.8% vs. 23.3%,
p>0.05).
CONCLUSIONS These real-life registry data proof that signiﬁcant
conduction disturbances with the necessity of pacemaker implanta-
tion occur frequently. The need of PMI alone does not affect mortality
signiﬁcantly. But further analysis is necessary to evaluate possible
side effects of PMI after TAVI.
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repositionable system with a nitinol stent frame and bovine pericar-
dial leaﬂets, which is increasingly utilized for transcatheter aortic
valve replacement (TAVR) in patients with severe native aortic ste-
nosis at high risk of conventional surgery. In this report, we describe
the procedural and early clinical results from an international multi-
center registry of Portico implantation in patients with degenerated
aortic bioprosthesis (Portico ViV).
METHODS Baseline demographics, procedural and clinical outcomes
were collected on standard case report forms and by the Valve-in-
Valve International Data network from 14 centers across three conti-
nents. Procedural endpoints included implantation success and cor-
onary obstruction. Clinical endpoints included death, myocardial
infarction (MI), stroke, major bleeding at 30 days as deﬁned by Valve
Academic Research consortium II (VARCII).
RESULTS 45 patients undergoing Portico ViV were included in anal-
ysis. The mean age was 79 7 years with STS (mortality) score of 74.
These procedures had mainly utilized peripheral arterial access (93%),
with transesophageal echocardiogram guidance (60%) for treatment
of surgical valve label size 21, >21-<25, and 25mm in 36, 38 and 27%
respectively. Four (9%) of the failed surgical bioprostheses were
stentless. Successful implantation was achieved in 44 (98%) cases
with no malposition events or clinically-evident coronary obstruction.
Post implantation valve area was 1.3 0.4 cm2, mean gradient of 17.1 
7.7 mmHg and moderate aortic insufﬁciency was observed in 3 (7%).
One death (2%) related to ischemic stroke occurred within 30 days.
Major bleeding and vascular complication in 5 (11%) and 1 (2%)
respectively. One patient required permanent pacemaker implanta-
tion (2%).
CONCLUSIONS Results from this international multicenter registry
show that Portico offers a safe and effective treatment of failed sur-
gical bioprosthesis with an added advantage of device retrievability,
resulting in low incidence of malpositioning and coronary obstruc-
tion. Additional studies and comparison with other transcatheter
devices should further determine the hemodynamic and clinical per-
formance of this device for selection of optimal treatment of high risk
patients with failed surgical bioprostheses.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is the
treatment option of choice for high surgical risk patients presenting
with severe symptomatic aortic stenosis. First generation devices were
limited by non-negligible TAVI-related complications including 2
paravalvular leak (PVL) and vascular complications that are predictors
of mortality. As a result, newer devices have been developed to over-
come these limitations. We aimed to compare procedural and clinical
outcomes between contemporary and ﬁrst generation devices.
METHODS A retrospective analysis was conducted of all patients that
underwent transfemoral TAVI between November 2007 and May 2015
at San Raffaele Scientiﬁc Institute, Milan, Italy. Patients treated with
an Edwards Sapien XT (Edwards LifeSciences, CA) or a CoreValve
(Medtronic, CA) were allocated to the ﬁrst-generation group (1G).
Patients treated with an Edwards Sapien 3 (Edwards LifeSciences),
Evolut R (Medtronic), Lotus (Boston Scientiﬁc, MA) or Direct Flow
(Direct Flow Medical, CA) valves were allocated to the second-gen-
eration group (2G).RESULTS 449 patients were included in the 1G, and 179 patients to
the 2G. Patients in the FG were older (83.4 vs. 82.1 years, p¼0.03), of
a higher risk proﬁle (Euroscore 10 vs. 9.5, p¼0.04) with a similar
gender preponderance (female: 61.2% vs. 61.4%, p¼0.79). Peri-pro-
cedurally, there was a lower incidence of major or life-threatening
bleeding complications in the 2G compared to the 1G (8.4% vs. 21.4%,
p<0.001) and 2 PVL (6.1% vs. 17.1%, p¼0.003) with no differences in
the rates of stroke (3.3% vs. 1.8%, p¼0.23) or PPM implantation (11.2%
vs. 12.7%, p¼0.6) respectively. Mortality at 30-days (3.6% vs. 1.4%,
p¼0.77) and at 1-year (11.2% vs. 12.7%, p¼0.81) were similar between
groups.
CONCLUSIONS This single-center retrospective study demonstrates
that newer generation TAVI devices are associated with a reduction
in 2 PVL and major and life-threatening bleeding events when
compared to ﬁrst generation devices. There were no differences in
short-term mortality. Longer-term follow-up are required to deter-
mine if these short-term procedural improvements are translated into
a longer-term outcome beneﬁt.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is
a treatment for patients with aortic stenosis deemed high risk
for aortic valve replacement (AVR). Advancing age independently
predictors mortality after AVR, so that most patients undergoing
TAVI are elderly. This study presents UK trends in activity and
outcomes for TAVI and AVR in patients aged 80 or over in the
“TAVI era”.
METHODS Data for all AVR and TAVI procedures between January-
2006 and December-2012 were sourced from (i) the UK Cardiac Sur-
gery Registry and (ii) the UK-TAVI Registry. Patient demographics, 30-
day mortality, postoperative length of stay (PLOS), 1-year and 5-year
survival were analyzed for four groups: TAVI, AVR, AVRþcoronary
artery bypass graft surgery (CABG), and AVRþother concomitant
surgery.
RESULTS Total aortic valve interventions increased between 2006
and 2012 from 1206 to 2668 (by 121%). Between 2006 and 2012, the
number of isolated AVR procedures increased from 485 to 808 (by
67%), while between 2007 and 2012, TAVI increased from 47 to 798
(by 160%). TAVI patients were older, more likely to be female, in
NYHA class IV, with prior cardiac surgery, renal, pulmonary, and
ventricular dysfunction, extra-cardiac arteriopathy, and neurological
disease than AVR patients (logistic EuroSCORE 23.513.7 vs. 13.69.5,
p<0.001). 30-day mortality was 10.55% (AVRþother), 5.61%
(AVRþCABG), 5.54% (TAVI), and 3.45% (AVR). Mean PLOS (days)
were 17.8 (AVRþother), 14.4 (AVRþCABG), 12.6 (AVR), and 9.1
(TAVI). 1-year survival was 89.6% (AVR), 85.1% (AVRþCABG), 81.9%
(TAVI), and 78.8% (AVRþother surgery). 5-year survival was 64.2%
(AVR), 59.7% (AVRþCABG), 56.5% (AVRþother surgery), and 43.4%
(TAVI).
CONCLUSIONS In 2007, TAVI made up only 3% of all aortic valve
interventions in patients 80 years. This had increased ten-fold to
almost 30% of all aortic valve interventions by 2012. Despite increased
age and risk scores, length of hospital stay was shorter, and 30-day
and 1-year mortality rates were comparable with other aortic valve
interventional groups.
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